Literature DB >> 28713684

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C Santini1, Siddharth Kunte2, Alexander Drilon1,3.   

Abstract

Entities:  

Year:  2017        PMID： 28713684      PMCID： PMC5504114          DOI： 10.21037/tlcr.2017.04.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  12 in total

1.  Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Authors:  Hartmut Koeppen; Wei Yu; Jiping Zha; Ajay Pandita; Elicia Penuel; Linda Rangell; Rajiv Raja; Sankar Mohan; Rajesh Patel; Rupal Desai; Ling Fu; An Do; Vaishali Parab; Xiaoling Xia; Tom Januario; Sharianne G Louie; Ellen Filvaroff; David S Shames; Ignacio Wistuba; Marina Lipkind; Jenny Huang; Mirella Lazarov; Vanitha Ramakrishnan; Lukas Amler; See-Chun Phan; Premal Patel; Amy Peterson; Robert L Yauch
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

3.  Signaling control by epidermal growth factor receptor and MET: rationale for cotargeting strategies in lung cancer.

Authors:  Eric B Haura; Matthew A Smith
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

4.  Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung.

Authors:  Martin Frederik Dietrich; Shirley Xiao Yan; Joan Hoff Schiller
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

5.  Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.

Authors:  Justin F Gainor; Matthew J Niederst; Jochen K Lennerz; Ibiayi Dagogo-Jack; Sara Stevens; Alice T Shaw; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2016-03-14       Impact factor: 15.609

6.  Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.

Authors:  Daisuke Matsubara; Shumpei Ishikawa; Oguni Sachiko; Hiroyuki Aburatani; Masashi Fukayama; Toshiro Niki
Journal:  Am J Pathol       Date:  2010-10-07       Impact factor: 4.307

7.  Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

Authors:  Michail Charakidis; Michael Boyer
Journal:  Transl Lung Cancer Res       Date:  2014-12

8.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

Authors:  Alexa B Schrock; Garrett M Frampton; James Suh; Zachary R Chalmers; Mark Rosenzweig; Rachel L Erlich; Balazs Halmos; Jonathan Goldman; Patrick Forde; Kurt Leuenberger; Nir Peled; Gregory P Kalemkerian; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Siraj M Ali; Sai-Hong Ignatius Ou
Journal:  J Thorac Oncol       Date:  2016-06-22       Impact factor: 15.609

9.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  David R Spigel; Thomas J Ervin; Rodryg A Ramlau; Davey B Daniel; Jerome H Goldschmidt; George R Blumenschein; Maciej J Krzakowski; Gilles Robinet; Benoit Godbert; Fabrice Barlesi; Ramaswamy Govindan; Taral Patel; Sergey V Orlov; Michael S Wertheim; Wei Yu; Jiping Zha; Robert L Yauch; Premal H Patel; See-Chun Phan; Amy C Peterson
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

10.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.

Authors:  Joanna H Tong; Sai F Yeung; Anthony W H Chan; Lau Y Chung; Shuk L Chau; Raymond Wai Ming Lung; Carol Y Tong; Chit Chow; Edith K Y Tin; Yau H Yu; Hui Li; Yi Pan; Wing P Chak; Calvin S H Ng; Tony S K Mok; Ka F To
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531
View more
  5 in total

1.  Erratum to combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Authors: 
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 2.  MET targeting: time for a rematch.

Authors:  Jonas P Koch; Daniel M Aebersold; Yitzhak Zimmer; Michaela Medová
Journal:  Oncogene       Date:  2020-02-07       Impact factor: 8.756

3.  Silencing of LOC389641 impairs cell proliferation and induces autophagy via EGFR/MET signaling in lung adenocarcinoma.

Authors:  Lei Xiao; Yu Li; Xiaofei Zeng; Zhiqing Zhou; Shengmin Hu; Shenglin Zhang; Yi Zhou; Zhan Zhang; Han Zhao; Huijie Zhao; David G Beer; Rui Mao; Guoan Chen
Journal:  Aging (Albany NY)       Date:  2020-12-09       Impact factor: 5.682

4.  Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.

Authors:  Mary B Kelley; Taylor J Geddes; Maria Ochiai; Noah M Lampl; W Wade Kothmann; Sara R Fierstein; Victoria Kent; Kathleen DeCicco-Skinner
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

5.  A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.

Authors:  Daisuke Sakai; Hyun Cheol Chung; Do-Youn Oh; Se Hoon Park; Shigenori Kadowaki; Yeul Hong Kim; Akihito Tsuji; Yoshito Komatsu; Yoon-Koo Kang; Kazunori Uenaka; Sameera R Wijayawardana; Volker Wacheck; Xuejing Wang; Ayuko Yamamura; Toshihiko Doi
Journal:  Cancer Chemother Pharmacol       Date:  2017-10-25       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.